OXFORD, UK, September 24th, 2014

PharmaVentures are delighted to announce that Aki von Roy has joined as an Associate, based in Auckland, New Zealand. He has over 30 years experience in Big Pharma and 16 years in biotech. Aki has been involved in over 18 start-up or merger ventures as director or investor.

His experience includes being Founder CEO of Proacta and CoDa Therapeutics and Founding Director of Corra Life Sciences (USA), Biomatters (NZ) and White Biotech (AUS). He is a former chairman of both private and publicly traded companies including Genesis R&D (NZ), Phylogica (AUS), Vital Foods (NZ) and Phytomedics (USA).

Aki von Roy is currently a Venture Partner at BioPacificVentures and an advisor to Direct Capital. He was previously a partner of Inventages (US$1.5 billion life science fund).

Dr Fintan Walton, CEO PharmaVentures, said “Aki has a unique insight into innovative healthcare in the Asia-Pacific region and he will be a great benefit to both PharmaVentures and its clients”.

Aki von Roy added “I am delighted to join PharmaVentures, a firm with a proven track record in deal making”.

Aki is the former European president of Bristol-Myers Squibb, where he was responsible for US$2.2 billion in sales, more than 7,500 employees and some 40 subsidiaries. In 1997, he retired from BMS to establish RvR Associates, a private investment firm specialising in health and related matters. 

- ends -